Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Allopurinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 4/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.31 |
| ▸ | CDK2 | P24941 | 4/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allopurinol SCHEMBL2563567 | 0.98 | CCNE2 (0.30) | CCNE2CCNE1CDK2 | |
| Allopurinol SCHEMBL4916844 | 0.77 | RET (0.57) | CDK2 | |
| 4-Hydroxyphenylpyruvic Acid SCHEMBL27347970 | 0.76 | FNTA (0.41) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL11362 | 0.74 | PI4KA (0.45) | — | |
| SCHEMBL4975500 | 0.74 | — | — | |
| SCHEMBL1128530 | 0.74 | PDE4A (0.38) | — | |
| Tisopurine SCHEMBL7160585 | 0.74 | — | — | |
| SCHEMBL17477110 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL1741651 | 0.72 | PI4KA (0.44) | — | |
| Hydrochloric Acid SCHEMBL14742344 | 0.72 | PI4KA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846525-B2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 2005-01-25 | — | — | US | claimed |
| US-6369237-B1 | ENZYME INHIBITORS OF DNA GLYCOLASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998039334-A9 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | — | 1999-02-18 | — | — | WO | claimed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| EP-4681719-A2 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX Therapeutics Inc. (CA) | 2026-01-21 | — | — | EP | disclosed |
| EP-3915565-B1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX THERAPEUTICS INC (CA) | 2025-09-10 | — | — | EP | disclosed |
| EP-4568704-A1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX Therapeutics Inc. (CA) | 2025-06-18 | — | — | EP | disclosed |
| CN-115611867-B | (1, 1-Trichloro-2) carbamate derivative and preparation method and application thereof | 中南大学 | 2024-04-30 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2024033705-A1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX THERAPEUTICS, INC. (CA) | 2024-02-15 | — | — | WO | disclosed |
| US-4024253-A | BENZANILIDE DERIVATIVES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-05-17 | — | — | US | disclosed |
| US-4011218-A | ANTI-GOUT, ANTI-HYPERURICEMIC | MERCK & CO., INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3973038-A | N-SUBSTITUTED PHENYL 2-HYDROXY BENZAMIDES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-08-03 | — | — | US | disclosed |
| US-3963731-A | TREATMENT OF GOUT AND HYPERURICEMIA | MERCK & CO., INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3947577-A | 1,2,4-TRIAZOLES | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
| US-3864341-A | 3-Morpholino-2-cyanoacrylamide | BURROUGHS WELLCOME CO | 1975-02-04 | — | — | US | disclosed |